Brunswick Corporation vs Smith & Nephew plc — how do they compare? Brunswick Corporation trades at $79.17 (market cap $5.21B), while Smith & Nephew plc trades at $30.14 (market cap $12.38B). The key difference: Smith & Nephew plc is far larger — about 2.4× Brunswick Corporation's market cap, and Smith & Nephew plc pays the higher dividend (2.66%). Which is the better fit depends on your goals.
| BC | SNN | |
|---|---|---|
Market Cap | $5.21B | $12.38B |
Sector | Consumer Cyclical | Health |
52-Week High | $89.22 | $38.70 |
52-Week Low | $58.75 | $28.73 |
Enterprise Value | $7.21B | $15.41B |
Dividend Yield | 2.19% | 2.66% |
Signals from Pluang's Aura AI — not financial advice
Brunswick Corporation (BC) trades at $80.27, down 0.2% on the day, with strong analyst support showing 71% buy ratings and an $85.33 consensus price target. Recent Q2 2026 earnings beat expectations with $1.56 EPS versus $1.19 expected, though the company remains unprofitable with negative net margins. Technical indicators show a bullish trend with current price near pivot point support at $81, while fundamentals reveal mixed performance with solid revenue but profitability challenges.
The outlook remains cautiously optimistic given strong institutional interest and recent earnings beats, but investors face risks from persistent negative profitability and high P/E valuation. Upside potential exists if the company can translate revenue stability into sustained earnings growth, though margin pressures and competitive threats warrant careful monitoring.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Trailing returns across standard periods
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →